Stemline

Submitted by:	Debra Sieminski, MS, PA-C
Company/Organization:	Stemline Therapeutics/ Medical Affairs
Address:	750 Lexington Avenue, New York, NY 10022
Phone:	1-646-502-1389
E-mail:	dsieminski@stemline.com
Date of Request:	April 24, 2019
NCCN Guidelines Panel:	Acute Myeloid Leukemia (AML)

Dear NCCN Acute Myeloid Leukemia Guidelines Panel:

On behalf of Stemline Therapeutics, Inc., I respectfully submit the enclosed information to the National Comprehensive Cancer Network (NCCN) Acute Myeloid Leukemia (AML) panel:

ELZONRIS™ (tagraxofusp) in patients with blastic plasmacytoid dendritic-cell neoplasm (BPDCN) [1]

- Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp in Blastic Plasmacytoid Dendritic Cell Neoplasm. *N Engl J Med* 2019;380:1628-37. DOI: 10.1056/NEJMoa1815105

Please consider the above publication published in the *New England Journal of Medicine* describing results from the clinical trial of ELZONRIS (tagraxofusp) in patients with BPDCN as supporting materials for the December 13, 2018 request for inclusion of ELZONRIS (tagraxofusp) in the NCCN clinical practice guidelines in AML.

We appreciate the opportunity to provide this additional information for review by the NCCN AML Panel. If you have any questions or need additional information, please do not hesitate to contact me at 1-646-502-1389 or via e-mail at dsieminski@stemline.com.

Thank you for your time and consideration.

Sincerely,

Debra Sieminski

Debra Sieminski, MS, PA-C
Medical Affairs

<u>Reference(s)</u>:

1. Pemmaraju N, Lane AA, Sweet KL, et al. Tagraxofusp (SL-401) in Blastic Plasmacytoid Dendritic Cell Neoplasm. *N Engl J Med* 2019; 380:1628-37. DOI: 10.1056/NEJMoa1815105